Article
A plain language summary of the results from the group of patients in the CHRYSALIS study with EGFR exon 20 insertion-mutated non-small-cell lung cancer who received amivantamab.
Future oncology (London, England) - 1 Oct 2023
Spira Alexander, Girard Nicolas, Krebs Matthew, Park Keunchil, Shu Catherine, Dougherty Lindsay, Cho Byoung Chul
Abstract excerpt
What is this summary about? This is a plain language summary of an article published in the Journal of Clinical Oncology in 2021. It describes the first results from 1 group of patients in the phase 1 CHRYSALIS study with epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins) mutations. This part of the CHRYSALIS study (called cohort D) investigated the bispecific antibody amivantamab (brand name...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.